Articles by Anna Rose Welch

51. FDA News Roundup: Pfizer, Eli Lilly, Vertex, And More 7/10/2015

    What FDA decisions have you missed recently?

52. Is Pharma Truly Equipped For Transparency? 7/8/2015

    As the call for transparency grows louder in the pharma industry, the question arises: are drugmakers equipped with all they need to be transparent — especially when it comes to demonstrating their drugs’ economic value?

53. How Are Virtual Biotechs Altering The R&D Landscape? 7/7/2015

    The term “virtual biotech” carries with it a certain revolutionary flair. Indeed, as Kent Pryor, COO of ZZ Biotech, describes, the virtual biotech represents a drastic shift in the biotech industry, and as such has a different approach to tackling the challenges of drug R&D.

54. Will Biotech Employment Continue To Rise As The Industry Evolves? 6/30/2015

    A report from the Bureau of Labor Statistics found that nationwide employment in “pharmaceutical and medicine manufacturing” sunk from 291,795 in 2003 to 277,113 in 2013, The Philadelphia Inquirer reported recently. But it’s not the same story for biotech R&D: employment hit 142,475 in 2013 — up from 135,424 in 2007.

55. FDA Roundup: Sanofi, Genentech, Apitope, Retrophin, And More 6/11/2015

    What regulatory decisions have you missed recently?

56. Will Pay-For-Performance Really Suit The Cancer Drug Space? 6/9/2015

    If Express Scripts should have its way, what would happen to inter-industry competition between the pharma players — specifically in the cancer space? If price tags are altered based off a drug’s performance, it seems to me the industry and its ways of quantifying success and leadership in the market will be faced with change as well — but it’s not entirely clear it will be what Express Scripts had in mind.

57. FDA News Roundup: Valeant, Pfizer, Boehringer Ingelheim, And More 5/29/2015

    What FDA decisions have you missed recently?

58. Pharma's Orphan Drug Binge: Redefining Corporate Social Responsibility? 5/26/2015

    A few months ago, Senator Elizabeth Warren launched a proposal for a “swear jar” bill that would require law-breaking Big Pharma companies to contribute 1 percent of the profits from each of their blockbuster drugs to NIH research. While this proposal was highly contested by members of the industry, I questioned if there couldn’t be a benefit to this bill apart from punishing law breakers and bolstering drug R&D. Would seeing pharma push more of its profits into research boost the industry’s image?   

59. FDA News Roundup: Baxter, Celgene, Agios, And More 5/22/2015

    What FDA decisions have you missed recently?

60. FDA News Roundup: Vertex, Merck KGaA , Bayer, And More 5/15/2015

    What recent FDA decisions have you missed lately?